Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2000 Nov;83(9):1124–1127. doi: 10.1054/bjoc.2000.1425

A randomized trial of 13-Cis retinoic acid in children with advanced neuroblastoma after high-dose therapy

J A Kohler 1, J Imeson 2, C Ellershaw 2, S O Lie 3
PMCID: PMC2363577  PMID: 11027423

Abstract

One hundred and seventy-five children with Stage 3 or 4 neuroblastoma who had obtained a good response to conventional therapy were randomly allocated to 13-Cis retinoic acid at a dose of 0.75 mg/kg/day or placebo for up to 4 years. Toxicity was mild but no advantage in event-free survival was shown for the children receiving retinoic acid. © 2000 Cancer Research Campaign

Keywords: 13-Cis retinoic acid, neuroblastoma

Full Text

The Full Text of this article is available as a PDF (51.1 KB).

Footnotes

On behalf of the European Neuroblastoma Study Group

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Brodeur G. M., Seeger R. C., Barrett A., Berthold F., Castleberry R. P., D'Angio G., De Bernardi B., Evans A. E., Favrot M., Freeman A. I. International criteria for diagnosis, staging, and response to treatment in patients with neuroblastoma. J Clin Oncol. 1988 Dec;6(12):1874–1881. doi: 10.1200/JCO.1988.6.12.1874. [DOI] [PubMed] [Google Scholar]
  2. Finklestein J. Z., Krailo M. D., Lenarsky C., Ladisch S., Blair G. K., Reynolds C. P., Sitarz A. L., Hammond G. D. 13-cis-retinoic acid (NSC 122758) in the treatment of children with metastatic neuroblastoma unresponsive to conventional chemotherapy: report from the Childrens Cancer Study Group. Med Pediatr Oncol. 1992;20(4):307–311. doi: 10.1002/mpo.2950200407. [DOI] [PubMed] [Google Scholar]
  3. Huang M. E., Ye Y. C., Chen S. R., Chai J. R., Lu J. X., Zhoa L., Gu L. J., Wang Z. Y. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood. 1988 Aug;72(2):567–572. [PubMed] [Google Scholar]
  4. Kraemer K. H., DiGiovanna J. J., Moshell A. N., Tarone R. E., Peck G. L. Prevention of skin cancer in xeroderma pigmentosum with the use of oral isotretinoin. N Engl J Med. 1988 Jun 23;318(25):1633–1637. doi: 10.1056/NEJM198806233182501. [DOI] [PubMed] [Google Scholar]
  5. Lippman S. M., Kessler J. F., Meyskens F. L., Jr Retinoids as preventive and therapeutic anticancer agents (Part I). Cancer Treat Rep. 1987 Apr;71(4):391–405. [PubMed] [Google Scholar]
  6. Lovat P. E., Irving H., Malcolm A. J., Pearson A. D., Redfern C. P. 9-cis retinoic acid--a better retinoid for the modulation of differentiation, proliferation and gene expression in human neuroblastoma. J Neurooncol. 1997 Jan;31(1-2):85–91. doi: 10.1023/a:1005785431343. [DOI] [PubMed] [Google Scholar]
  7. Matthay K. K., Villablanca J. G., Seeger R. C., Stram D. O., Harris R. E., Ramsay N. K., Swift P., Shimada H., Black C. T., Brodeur G. M. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med. 1999 Oct 14;341(16):1165–1173. doi: 10.1056/NEJM199910143411601. [DOI] [PubMed] [Google Scholar]
  8. Miller W. H., Jr, Jakubowski A., Tong W. P., Miller V. A., Rigas J. R., Benedetti F., Gill G. M., Truglia J. A., Ulm E., Shirley M. 9-cis retinoic acid induces complete remission but does not reverse clinically acquired retinoid resistance in acute promyelocytic leukemia. Blood. 1995 Jun 1;85(11):3021–3027. [PubMed] [Google Scholar]
  9. Peto R., Pike M. C., Armitage P., Breslow N. E., Cox D. R., Howard S. V., Mantel N., McPherson K., Peto J., Smith P. G. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design. Br J Cancer. 1976 Dec;34(6):585–612. doi: 10.1038/bjc.1976.220. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Reynolds C. P., Kane D. J., Einhorn P. A., Matthay K. K., Crouse V. L., Wilbur J. R., Shurin S. B., Seeger R. C. Response of neuroblastoma to retinoic acid in vitro and in vivo. Prog Clin Biol Res. 1991;366:203–211. [PubMed] [Google Scholar]
  11. Thiele C. J., Reynolds C. P., Israel M. A. Decreased expression of N-myc precedes retinoic acid-induced morphological differentiation of human neuroblastoma. 1985 Jan 31-Feb 6Nature. 313(6001):404–406. doi: 10.1038/313404a0. [DOI] [PubMed] [Google Scholar]
  12. Villablanca J. G., Khan A. A., Avramis V. I., Seeger R. C., Matthay K. K., Ramsay N. K., Reynolds C. P. Phase I trial of 13-cis-retinoic acid in children with neuroblastoma following bone marrow transplantation. J Clin Oncol. 1995 Apr;13(4):894–901. doi: 10.1200/JCO.1995.13.4.894. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES